SEARCH

SEARCH BY CITATION

References

  • 1
    Bak T, Wachs M, Trotter J, Everson J, Trouillot T, Kugelmas M, et al. Adult-to-adult living donor liver transplantation using right-lobe grafts: results and lessons learned from a single-center experience. Liver Transpl 2001; 7: 680686.
  • 2
    Miller CM, Gondolesi GE, Florman S, Matsumoto C, Munoz L, Yoshizumi T, et al. One hundred nine living donor liver transplants in adults and children: a single center experience. Ann Surg 2001; 234: 301312.
  • 3
    Grewal HP, Thistlethwaite R Jr, Loss GE, Fisher JS, Cronin DC, Siegel CT, et al. Complications in 100 living-liver donors. Ann Surg 1998; 228: 214219.
  • 4
    Inomata Y, Tanaka K, Uemoto S, Asonuma K, Egawa H, Kiuchi T, et al. Living donor liver transplantation: an 8 year experience with 379 consecutive cases. Transplant Proc 1999; 31: 381.
  • 5
    Marcos A, Ham JM, Fisher RA, Olzinski AT, Posner MP. Single center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe. Liver Transpl 2000; 6: 296301.
  • 6
    Ghobrial RM, Sammy S, Lassman C, Lu DSK, Raman S, Limanond P, et al. Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver Transpl 2002; 8: 901909.
  • 7
    Emond JC, Renz JF, Ferrell LD, Rosenthal P, Lim RC, Roberts JP, et al. Functional analysis of grafts from living donors. Implications for the treatment of older recipients. Ann Surg 1996; 224: 544554.
  • 8
    Gaglio PJ, Malireddy S, Russo M, LaPointe-Rudow D, Emond JC, Brown RS Jr. Hepatitis C recurrence in recipients of grafts from living vs. cadaveric living donors [Abstract]. Hepatology 2002; 36: 265A.
  • 9
    Rodriguez-Luna H, Vargas H, De Petris G, Byrne T, Moss A, Mulligan D, et al. Hepatitis C virus recurrence in living donor liver transplantation vs. cadaveric liver transplantation [Abstract]. Am J Transplant 2003; 3(suppl 5): 160A.
  • 10
    Ghobrial RM, Amersi F, Farmer DG, Chen P, Anselmo DM, Baquerizo A, et al. Rapid and severe early HCV recurrence following adult living donor liver transplantation [Abstract]. Am J Transplant 2002; 2: 163A.
  • 11
    Shiffman ML, Fisher RA, Stravitz RT, Luketic VA, Sanyal AJ, Mills AS, et al. Histologic analysis of recurrent hepatitis C virus infection following living donor and cadaveric liver transplantation [Abstract]. Am J Transplant 2003; 3(suppl 5): 203.
  • 12
    Brown RS Jr, Russo MW, Lai M, Shiffman ML, Richardson MC, Everhart JE, Hoofnagle JH. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003; 348: 818825.
  • 13
    Honda M, Kaneko S, Matsushita E, Kobayashi K, Abell GA, Lemon SM. Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. Gastroenterology 2000; 118: 152162.
  • 14
    Trotter JF, Schiano T, Wachs M, Kim-Schluger L, Bak T, Everson G, et al. Preliminary report: hepatitis C occurs earlier and is more severe in living donor liver transplant recipients [Abstract]. Am J Transplant 2001; 1: 316A.
  • 15
    Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8: S19S27.
  • 16
    Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823830.
  • 17
    US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 11101115.
  • 18
    Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493499.
  • 19
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(4 suppl 1): S107S114.
  • 20
    Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756763.
  • 21
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 14531457.
  • 22
    Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442450.
  • 23
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with Hepatitis C. Liver Transpl 2002; 8: 4046.
  • 24
    Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 10641070.
  • 25
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.